Article Details

Goldman Sachs maintains 'neutral' on Dynavax with $20 target - Investing.com

Retrieved on: 2024-05-14 19:52:42

Tags for this article:

Click the tags to see associated articles and topics

Goldman Sachs maintains 'neutral' on Dynavax with $20 target - Investing.com. View article details on hiswai:

Excerpt

On Tuesday, Goldman Sachs reiterated a Neutral rating for Dynavax (NASDAQ:DVAX) Technologies (NASDAQ:DVAX), maintaining a price target of $20.00.

Article found on: www.investing.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo